Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients - A systematic review

Martijn Simons, Bram Ramaekers, Andrea Peeters, Joanne Mankor, Marthe Paats, Joachim Aerts, Wim van Harten, Valesca Retel, Manuela Joore*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Article number103035
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume153
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Non-small cell lung cancer
  • Targeted therapies
  • Immunotherapies
  • Survival analysis
  • Overall survival
  • RANDOMIZED PHASE-III
  • OPEN-LABEL
  • 1ST-LINE TREATMENT
  • CARBOPLATIN-PACLITAXEL
  • COMPARING GEFITINIB
  • CHEMOTHERAPY
  • ERLOTINIB
  • DOCETAXEL
  • ADENOCARCINOMA
  • TRIAL

Cite this